News | August 23, 2024
Lupin receives Health Canada approval for biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The facility is a part of Lupin Manufacturing Solutions
Subscribe To Our Newsletter & Stay Updated
